Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
July-2017 Volume 14 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
July-2017 Volume 14 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages

  • Authors:
    • Yanhua Fu
    • Yang Zhao
    • Bin Huang
  • View Affiliations / Copyright

    Affiliations: Department of Internal Medicine, VIP Ward, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
  • Pages: 862-866
    |
    Published online on: June 7, 2017
       https://doi.org/10.3892/etm.2017.4551
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Macrophage foam cell formation plays a pivotal role in the pathogenesis of atherosclerosis. The protein Tribbles homolog 1 (Trib1), a member of the Tribbles protein family, functions as an adaptor or scaffold protein. Recent studies have indicated its implication in lipoprotein metabolism. In the present study, the role of Trib1 in macrophage foam cell formation was investigated. Oil red O staining was used to analyze intracellular lipid deposition, while the effects of Trib1 overexpression on cholesterol efflux were also examined. Furthermore, quantitative polymerase chain reaction and western blot analysis were performed to measure the expression levels of genes involved in cholesterol efflux. The results revealed that overexpression of Trib1 inhibited lipid accumulation in oxidized low density lipoprotein-treated THP‑1 macrophages and facilitated macrophage cholesterol efflux to apolipoprotein A‑I. Overexpression of Trib1 also upregulated the expression levels of ATP‑binding cassette A1 (ABCA1), ABCG1, liver X receptor α (LXRα) and peroxisome proliferator‑activated receptor γ (PPARγ). In addition, silencing of LXRα or PPARγ via small interfering RNA transfection significantly reversed the Trib1‑induced cholesterol efflux. In conclusion, Trib1 inhibits macrophage foam cell formation and enhances cholesterol efflux, which is associated with regulation of the PPARγ, LXRα, ABCA1 and ABCG1 expression levels.

Introduction

Atherosclerosis is a chronic inflammatory disease, characterized by progressive accumulation of lipids and cellular and fibrous elements in the arterial wall (1,2). Macrophages are involved in various aspects of atherosclerosis (3,4). In particular, macrophage-mediated uptake of modified low-density lipoprotein (LDL) and subsequent transformation into foam cells serve a critical role in the development of atherosclerosis (5). Lipid accumulation in macrophages leads to the activation of signaling pathways that involve activation of peroxisome proliferator-activated receptor-γ (PPARγ) and liver X receptor α (LXRα), which are transcription factors controlling the macrophage cholesterol homeostasis (6). Activated PPARγ and LXRα are synergistically implicated in the transactivation of several genes, such as the ATP-binding cassette transporter (ABCA1) and ABCG1, the products of which are involved in regulating the macrophage cholesterol efflux and triggering reverse cholesterol transport (7), which is part of a ‘self-protection mechanism’ for macrophages.

The protein Tribbles homolog 1 (Trib1), a member of the recently identified Tribbles protein family, is considered to function as an adaptor or scaffold protein (8). Burkhardt et al have reported that hepatic expression of Trib1 regulates the plasma levels of LDL-cholesterol (LDL-C), very-LDL (VLDL), and triglyceride (TG) in mice (9). In addition, Satoh et al demonstrated that mice lacking Trib1 expression in hematopoietic cells developed hypertriglyceridemia and insulin resistance in response to a high-fat diet (10). These authors also suggested that Trib1 is critical for adipose tissue maintenance and inhibition of metabolic disorders by regulating the differentiation of tissue-resident M2-like macrophages (10). The aforementioned findings indicate that Trib1 serves an important role in lipoprotein metabolism. However, the functions of Trib1 in cholesterol efflux remain largely unknown.

In the present study, the THP-1 cell model was used to explore the role of Trib1 in the formation of macrophage foam cells during atherosclerosis. The effect of overexpression of Trib1 on lipid accumulation and cholesterol efflux was investigated in macrophages, and associated molecular mechanisms were also explored.

Materials and methods

Cell culture and differentiation

THP-1 human monocytic cell line was purchased from the Shanghai Cell Institute of the Chinese Academy of Sciences (Shanghai, China). THP-1 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 µg/ml) at 37°C in 5% CO2. To differentiate into macrophages, THP-1 monocytes were exposed to 160 nM phorbol-12-myristate-13-acetate (Sigma-Aldrich, St. Louis, MO, USA) for 72 h. The differentiated macrophages were washed three times with phosphate-buffered saline (PBS) and incubated in fresh serum-free medium containing 50 µg/ml oxidized LDL (ox-LDL; Yiyuan Biotechnology Co., Ltd., Guangzhou, China) for 48 h.

Cell transfection

In order to investigate the effect of Trib1 overexpression in THP-1 macrophages, the cells were transfected with pCMV6-Entry-Trib1 (Trib1 overexpressing group) or pCMV6-Entry vector (empty vector group) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instructions. The pCMV6-Entry-Trib1 and empty vector were purchased from OriGene Technologies, Inc. (Rockville, MD, USA). Non-transfected THP-1 macrophages were used as a control. For small interfering RNA (siRNA)-mediated knockdown experiments, THP-1 macrophages were co-transfected with pCMV6-Entry-Trib1 and LXRα siRNA or PPARγ siRNA (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). After 24 h of transfection, cells were incubated with ox-LDL (50 µg/ml) in serum-free medium for an additional 24 h before conducting the expression or functional studies.

Morphological examination

Non-transfected or transfected THP-1 macrophages were cultured in chamber slides in serum-free medium. After 24-h incubation, cells were washed three times in PBS and fixed with 5% formalin solution for 30 min. Next, the cells were stained with oil red O (Sigma-Aldrich) for 30 min, and counterstained with hematoxylin for 5 min. Finally, cells were analyzed by light microscopy (Axio Imager 2; Zeiss, Oberkochen, Germany). Five selected high-power fields at a magnification of ×400 were randomly selected for examination. Semi-quantitative analysis of oil red O positive staining was conducted by the ImageJ software (version 1.48, National Institutes of Health, Bethesda, MD, USA).

Cholesterol efflux

In order to investigate the cholesterol efflux, non-transfected or transfected THP-1 macrophages (5×105 cells/well) were seeded into 12-well plates, labeled with 0.5 µCi/ml [3H]-cholesterol (PerkinElmer, Waltham, MA, USA) in media containing 0.2% bovine serum albumin for 24 h and then washed with fresh media. Then, cells were washed with PBS and incubated in the presence of 10 µg/ml apolipoprotein A-I (apoA-I; EMD Millipore, Billerica, MA, USA) for 18 h. Medium and cell-associated [3H] cholesterol were examined through liquid scintillation counting. The percentage of cholesterol efflux was calculated with the following equation: [Total media radioactivity/(total cellular radioactivity + total media radioactivity)] × 100%.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis

Total RNA was isolated from THP-1 macrophages with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA concentration was measured by spectrophotometry with a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, Inc.). cDNA synthesis was performed using the PrimeScript RT reagent Kit according to the manufacturer's instructions (catalog no. RR037A; Takara, Shiga, Japan). qPCR analysis was then conducted using a Light Cycler-FastStart DNA Master SYBR-Green I kit (Roche Molecular Biochemicals, Manheim, Germany). The sequences of the primers used in the current study are shown in Table I. Data were analyzed with the 2−ΔΔCq relative quantification method (11). Values are presented as fold change relative to control cells.

Table I.

Primers used in quantitative real-time polymerase chain reaction analysis.

Table I.

Primers used in quantitative real-time polymerase chain reaction analysis.

GeneForward primerReverse primer
ABCA1 5′-ATCTCATAGTATGGAAGAATGTGAAGCT-3′ 5′-CGTACAACTATTGTATAACCATCTCCAAA-3′
ABCG1 5′-AGGTCTCAGCCTTCTAAAGTTCCTC-3′ 5′-TCTCTCGAAGTGAATGAAATTTATCG-3′
LXRα 5′-TCAGCATCTTCTCTGCAGACCGG-3′ 5′-TCATTAGCATCCGTGGGAACA-3′
PPARγ 5′-TGAACAAAGACGGGATG-3′ 5′-TCAAACTTGGGTTCCATGAT-3′
β-actin 5′-TCATGAAGTGTGACGTTGACATCCGT-3′ 5′-CTTAGAAGCATTTGCGGTGCACGATG-3′

[i] ABC, ATP-binding cassette transporter; LXRα, liver X receptor α; PPARγ, peroxisome proliferator-activated receptor γ.

Western blot analysis

After the indicated treatment, cells were washed with ice-cold PBS and harvested in lysis buffer [30 mM HEPES, pH 7.6, 30 mM NaCl, 1% Nonidet P-40 (vol/vol), 10% glycerol (vol/vol), 50 mM NaF and 10 mM Na pyrophosphate] supplemented with 5 mM Na orthovanadate and protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA). Cell lysates were collected by centrifugation at 14,000 × g for 5 min at 4°C, and the protein concentration in total lysates was analyzed by the BCA protein assay kit (Pierce; Thermo Fisher Scientific, Inc.). Next, 20 µg total protein were subjected to 10% SDS-PAGE and transferred onto a nitrocellulose membrane (Whatman; Sigma-Aldrich). Membranes were blocked overnight with 5% non-fat dry milk in Tris-buffered saline containing 0.1% Tween-20 for 1 h at room temperature. The membranes were then probed overnight at 4°C with the following primary antibodies: Anti-TRIB1 (ab137717; 1:200), anti-ABCA1 (ab18180; 1:200), anti-ABCG1 (ab155918; 1:200), anti-LXRα (ab82774; 1:200), anti-PPARγ (ab24509; 1:200) and anti-β-actin (ab97379; 1:500; all from Abcam, Cambridge, MA, USA). Subsequently, samples were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (ab97265; 1:2,000 dilution) or goat anti-rabbit IgG (ab97200; 1:2,000 dilution; both from Abcam) for 1 h at room temperature. Final detection was performed using an ECL chemiluminescence system (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and quantitative results were obtained using Quantity One software (version 4.4.0; Bio-Rad Laboratories, Inc.).

Statistical analysis

All data are expressed as the mean ± standard deviation. Results were analyzed by one-way analysis of variance, followed by the Tukey's post hoc test, using SPSS version 11.0 software (SPSS, Inc., Chicago, IL, USA). P-values of <0.05 were considered to indicate differences that were statistically significant.

Results

Overexpression of Trib1 inhibits lipid accumulation and enhances cholesterol efflux in ox-LDL-stimulated THP-1 macrophages

Transfection of THP-1 macrophages with pCMV6-Entry-Trib1 resulted in significant overexpression of Trib1 (increased by ~8.6-fold), as determined by western blot analysis (P<0.05 vs. vector-transfected cells; Fig. 1A). Subsequently, in order to explore the intracellular lipid deposition in response to Trib1 overexpression in THP-1 macrophages, the intracellular cholesterol levels were analyzed. Forced expression of Trib1 significantly inhibited lipid accumulation as evidenced by oil red O staining (P<0.05; Fig. 1B and C). Furthermore, exogenous expression of Trib1 significantly enhanced the apoA-I-mediated cholesterol efflux in ox-LDL-stimulated THP-1 cells (P<0.05; Fig. 1D). These results revealed that Trib1 inhibited the intracellular lipid deposition due to increased apoA-I-mediated cholesterol efflux in THP-1 macrophages.

Figure 1.

Effects of Trib1 on intracellular lipid accumulation and cholesterol efflux in THP-1 macrophages. Cells were transfected with pCMV6-Entry-Trib1 (Trib1 group) or pCMV6-Entry (Vector group) for 24 h and then incubated with 50 µg/ml ox-LDL in serum-free medium for 24 h. (A) Expression of Trib1 protein, as determined by western blot analysis. (B and C) Lipid accumulation in cells was investigated by oil red O staining (magnification, ×100). (D) Intracellular apolipoprotein A-I-mediated cholesterol efflux. Data are representative of the mean ± standard deviation of duplicate wells from three independent experiments. *P<0.05. Trib1, Tribbles homolog 1; ox-LDL, oxidized low-density lipoprotein.

Forced expression of Trib1 increases the expression of ABCA1, ABCG1, LXRα and PPARγ

RT-qPCR analysis demonstrated that overexpression of Trib1 significantly increased the ABCA1, ABCG1, LXRα and PPARγ mRNA expression levels in ox-LDL-stimulated THP-1 macrophages (P<0.05; Fig. 2A). Similarly, western blot analysis indicated that Trib1 overexpression led to a significant (1.5–2-fold) increase in the levels of ABCA1, ABCG1, LXRα, and PPARγ protein (P<0.05; Fig. 2B).

Figure 2.

Effects of Trib1 on the (A) mRNA and (B) protein expression levels of ABCA1, ABCG1, LXRα and PPARγ in THP-1 macrophages, determined by quantitative polymerase chain reaction and western blot analysis, respectively. THP-1 macrophages were transfected with pCMV6-Entry-Trib1 or pCMV6-Entry for 24 h and then incubated with 50 µg/ml ox-LDL in serum-free medium for a further 24 h. β-actin served as an internal control. Data are presented as the mean ± standard deviation of duplicate wells from three experiments. *P<0.05. Trib1, Tribbles homolog 1; ox-LDL, oxidized low-density lipoprotein; ABC, ATP-binding cassette transporter; LXRα, liver X receptor α; PPARγ, peroxisome proliferator-activated receptor γ.

LXRα or PPARγ siRNA transfection attenuates Trib1-induced cholesterol efflux

Silencing of LXRα by siRNA transfection significantly decreased Trib1-induced cholesterol efflux in THP-1 macrophages transfected with pCMV6-Entry-Trib1, when compared with the cholesterol efflux in THP-1 macrophages-transfected with pCMV6-Entry-Trib1 and a control siRNA (P<0.05; Fig. 3A). Furthermore, knockdown of PPARγ by siRNA transfection also significantly attenuated the Trib1-induced cholesterol efflux compared with transfection with a control siRNA (P<0.05; Fig. 3B).

Figure 3.

Effects of overexpression of Trib1 on apoA-I-mediated cholesterol efflux in LXRα-silenced or PPARγ-silenced and ox-LDL-stimulated THP-1 macrophages. Cells were co-transfected with pCMV6-Entry-Trib1 and (A) LXRα siRNA or (B) PPARγ siRNA for 24 h, incubated with ox-LDL in serum-free medium for a further 24 h and then the intracellular apolipoprotein A-I-mediated cholesterol efflux was determined. Data are presented as the mean ± standard deviation of duplicate wells from three experiments. *P<0.05. Trib1, Tribbles homolog 1; ox-LDL, oxidized low-density lipoprotein; LXRα, liver X receptor α; PPARγ, peroxisome proliferator-activated receptor γ.

Discussion

Genome-wide association studies identified that the genetic locus at human chromosome 8q24 has minor alleles associated with lower levels of plasma TG and LDL-C, as well as higher levels of high density lipoprotein-cholesterol (12,13). This locus contains only one annotated gene, namely Trib1 (12,13). Burkhardt et al demonstrated that Trib1 is a regulator of lipoprotein metabolism in mice (9), and that hepatic-specific overexpression of Trib1 reduces the plasma TG and cholesterol levels by reducing VLDL production (9). Conversely, Trib1-knockout mice exhibited elevated levels of plasma TG and cholesterol due to increased VLDL production (9). In addition, Satoh et al suggested that Trib1 is critical for adipose tissue maintenance and suppression of metabolic disorders by controlling the differentiation of tissue-resident M2-like macrophages (10). These results indicate that Trib1 is implicated in the regulation of lipid metabolism. However, the underlying mechanism throughout which Trib1 regulates lipid metabolism at the molecular level remains unclear. In the present study, the effect of Trib1 overexpression on lipid accumulation and intracellular cholesterol efflux was investigated in ox-LDL-stimulated THP-1 macrophages. Transiently transfected THP-1 macrophages were used to examine the role of Trib1 in cholesterol homeostasis. The present results indicated that forced expression of Trib1 decreased intracellular lipid accumulation and enhanced cholesterol efflux in ox-LDL-exposed THP-1 macrophages.

PPARγ is a nuclear receptor that regulates immunity and inflammation (14,15). Upon binding with its ligands, PPARγ activates and promotes cholesterol efflux from macrophages through the PPARγ-LXRα-ABCA1 signaling pathway (16). LXRα is a nuclear receptor transcription factor (17) that when activated binds to the LXR response element in the promoter region of the LXR target genes, such as ABCA1 and ABCG1, in order to regulate the expression of such genes (18). The current study examined the impact of overexpression of Trib1 on the expression of genes involved in macrophage cholesterol efflux. After transient transfection with pCMV6-Entry-Trib1, cellular responses were analyzed. Forced expression of Trib1 was found to induce the expression of ABCA1, ABCG1, LXRα and PPARγ at the mRNA and protein levels. Furthermore, silencing of PPARγ or targeting LXRα by siRNA attenuated the Trib1-induced cholesterol efflux, indicated that Trib1-mediated cholesterol efflux may occur through the PPARγ-LXRα-ABCA1/ABCG1 signaling pathway. However, it is unclear how Trib1 regulates the PPARγ-LXRα-ABCA1/ABCG1 signaling pathway. It has been suggested that CD36 activates PPARγ through the extracellular signal-regulated kinase (ERK)1/2-dependent cyclooxygenase 2 expression in macrophages, thereby promoting cholesterol and phospholipid efflux from macrophages (19). Similarly, sesamin has been demonstrated to improve macrophage cholesterol efflux through the PPARγ1-LXRα pathway, which is dependent on mitogen-activated protein kinase (MAPK) signaling (20). It appears that MAPK signaling serves an important role in cholesterol efflux. Overexpression of Trib1 enhances ERK phosphorylation, reducing the apoptosis of leukemic cells upon interleukin-3 depletion and may be a key mediator between the RTK-MAPK pathway and the C/EBP transcription factor in myeloid leukemogenesis (21). In the present study, it was hypothesized that Trib1-mediated cholesterol efflux may occur through the MAPK signaling pathway; however, further experiments are required to test this hypothesis.

Although Trib1 overexpression leads to enhanced cholesterol efflux from ox-LDL-loaded macrophages, it is still unclear whether Trib1 is necessary for cholesterol efflux. The effects of silencing Trib1 on cholesterol efflux should be investigated further.

In conclusion, the results of the present study indicate that Trib1 inhibits lipid accumulation and enhances cholesterol efflux in ox-LDL-exposed THP-1 macrophages through the PPARγ-LXRα-ABCA1/ABCG1 signaling pathway. These data provide a rationale for investigating the potential of delivering Trib1 in the prevention of macrophage foam cell formation and atherosclerosis.

References

1 

Moss JW, Davies TS, Garaiova I, Plummer SF, Michael DR and Ramji DP: A Unique combination of nutritionally active ingredients can prevent several key processes associated with atherosclerosis in vitro. PLoS One. 11:e01510572016. View Article : Google Scholar : PubMed/NCBI

2 

Narasimhulu C Aluganti, Fernandez-Ruiz I, Selvarajan K, Jiang X, Sengupta B, Riad A and Parthasarathy S: Atherosclerosis-do we know enough already to prevent it? Curr Opin Pharmacol. 27:92–102. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Conti P and Shaik-Dasthagirisaeb Y: Atherosclerosis: A chronic inflammatory disease mediated by mast cells. Cent Eur J Immunol. 40:380–386. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Rojas J, Salazar J, Martínez MS, Palmar J, Bautista J, Chávez-Castillo M, Gómez A and Bermúdez V: Macrophage heterogeneity and plasticity: Impact of macrophage biomarkers on atherosclerosis. Scientifica (Cairo). 2015:8512522015.PubMed/NCBI

5 

Glass CK and Witztum JL: Atherosclerosis: The road ahead. Cell. 104:503–516. 2001. View Article : Google Scholar : PubMed/NCBI

6 

Bogachev O, Majdalawieh A, Pan X, Zhang L and Ro HS: Adipocyte enhancer-binding protein 1 (AEBP1) (a novel macrophage proinflammatory mediator) overexpression promotes and ablation attenuates atherosclerosis in ApoE (−/−) and LDLR (−/−) mice. Mol Med. 17:1056–1064. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Zhou Q, Mei Y, Shoji T, Han X, Kaminski K, Oh GT, Ongusaha PP, Zhang K, Schmitt H, Moser M, et al: Rho-associated coiled-coil-containing kinase 2 deficiency in bone marrow-derived cells leads to increased cholesterol efflux and decreased atherosclerosis. Circulation. 126:2236–2247. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, Caunt JC, Oxley KM, Wyllie DH, Polgar T, Harte M, et al: Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J Biol Chem. 279:42703–42708. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Burkhardt R, Toh SA, Lagor WR, Birkeland A, Levin M, Li X, Robblee M, Fedorov VD, Yamamoto M, Satoh T, et al: Trib1 is a lipid- and myocardial infarction-associated gene that regulates hepatic lipogenesis and VLDL production in mice. J Clin Invest. 120:4410–4414. 2010. View Article : Google Scholar : PubMed/NCBI

10 

Satoh T, Kidoya H, Naito H, Yamamoto M, Takemura N, Nakagawa K, Yoshioka Y, Morii E, Takakura N, Takeuchi O and Akira S: Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages. Nature. 495:524–528. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

12 

Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, et al: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 40:189–197. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, Timpson NJ, Najjar SS, Stringham HM, et al: Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 40:161–169. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Glass CK and Saijo K: Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol. 10:365–376. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Villacorta L, Schopfer FJ, Zhang J, Freeman BA and Chen YE: PPARgamma and its ligands: Therapeutic implications in cardiovascular disease. Clin Sci (Lond). 116:205–218. 2009. View Article : Google Scholar : PubMed/NCBI

16 

Bouhlel MA, Staels B and Chinetti-Gbaguidi G: Peroxisome proliferator-activated receptors-from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. J Intern Med. 263:28–42. 2008.PubMed/NCBI

17 

Huang C: Natural modulators of liver X receptors. J Integr Med. 12:76–85. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Zelcer N and Tontonoz P: Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 116:607–614. 2006. View Article : Google Scholar : PubMed/NCBI

19 

Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S and Ong H: CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc Res. 83:457–464. 2009. View Article : Google Scholar : PubMed/NCBI

20 

Majdalawieh AF and Ro HS: The anti-atherogenic properties of sesamin are mediated via improved macrophage cholesterol efflux through PPARγ1-LXRα and MAPK signaling. Int J Vitam Nutr Res. 84:79–91. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Yokoyama T, Kanno Y, Yamazaki Y, Takahara T, Miyata S and Nakamura T: Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis. Blood. 116:2768–2775. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Fu Y, Zhao Y and Huang B: Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages. Exp Ther Med 14: 862-866, 2017.
APA
Fu, Y., Zhao, Y., & Huang, B. (2017). Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages. Experimental and Therapeutic Medicine, 14, 862-866. https://doi.org/10.3892/etm.2017.4551
MLA
Fu, Y., Zhao, Y., Huang, B."Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages". Experimental and Therapeutic Medicine 14.1 (2017): 862-866.
Chicago
Fu, Y., Zhao, Y., Huang, B."Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages". Experimental and Therapeutic Medicine 14, no. 1 (2017): 862-866. https://doi.org/10.3892/etm.2017.4551
Copy and paste a formatted citation
x
Spandidos Publications style
Fu Y, Zhao Y and Huang B: Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages. Exp Ther Med 14: 862-866, 2017.
APA
Fu, Y., Zhao, Y., & Huang, B. (2017). Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages. Experimental and Therapeutic Medicine, 14, 862-866. https://doi.org/10.3892/etm.2017.4551
MLA
Fu, Y., Zhao, Y., Huang, B."Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages". Experimental and Therapeutic Medicine 14.1 (2017): 862-866.
Chicago
Fu, Y., Zhao, Y., Huang, B."Tribbles homolog 1 enhances cholesterol efflux from oxidized low-density lipoprotein-loaded THP-1 macrophages". Experimental and Therapeutic Medicine 14, no. 1 (2017): 862-866. https://doi.org/10.3892/etm.2017.4551
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team